Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
JOHNSON & JOHNSON CEO and Chairman Joaquin Duato reported multiple equity transactions related to the company’s long-term incentive plan. On February 15, 2026, he received a grant of 131,734 employee stock options and 9,459 restricted share units, each representing the right to receive one share of common stock upon vesting.
Across February 13 and 15, 2026, previously awarded RSUs and performance share units vested and were converted into common stock through several exercises coded “M”. In connection with these vestings, common shares coded “F” were withheld at prices around $243.45–$244.55 per share to satisfy tax obligations. Duato also reports indirect holdings of 998 common shares through a 401(k) plan and 30,852 shares held by his spouse.
Johnson & Johnson executive Vanessa Broadhurst, EVP of Global Corporate Affairs, reported several equity transactions. On February 17, 2026, she completed an open-market sale of 6,197 shares of Common Stock at a weighted average price of $243.39 per share, leaving her with 23,003 shares of common stock held directly.
On February 13 and 15, 2026, previously granted Restricted Share Units (RSUs) and Performance Share Units (PSUs) vested and were converted into common shares, with a portion of those shares withheld to cover tax obligations. The filing also shows new equity awards under Johnson & Johnson’s Long-Term Incentive Plan, including 14,405 employee stock options and additional RSUs that generally vest in three equal annual installments beginning on the first anniversary of their grant dates.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell common stock of the issuer. The filing lists proposed sales of 13,625 shares (option granted 02/13/2017) and 8,998 shares (option granted 02/12/2018), with an indicated date of 02/18/2026.
This notice reports proposed dispositions under issuer-granted options and indicates cash settlement; timing and expected proceeds are not stated in the excerpt.
Johnson & Johnson insider plans Rule 144 stock sale. A holder has filed to sell 6,197 shares of Johnson & Johnson common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,508,299.61 and 2,409,898,936 shares reported outstanding.
The shares to be sold were acquired as compensation through restricted stock vesting from the issuer on several dates in 2025 and 2026, including 5,110 shares vesting on February 13, 2026. The seller represents they are not aware of undisclosed material adverse information about the company.
Shareholder James Swanson filed a Rule 144 notice to sell 20,521 Johnson & Johnson common shares with an aggregate market value of $4,980,510.40. The shares are planned to be sold on the NYSE around 02/17/2026 through Fidelity Brokerage Services LLC.
These shares were acquired on 02/17/2026 via options granted on 02/08/2021, with the 20,521 shares paid for in cash. Over the prior three months, Swanson sold 41,559 Johnson & Johnson common shares on 02/13/2026 for gross proceeds of $10,129,245.92.
An affiliate of the issuer filed a notice to sell 89,654 shares of common stock under Rule 144. The shares are planned to be sold on the NYSE through Fidelity Brokerage Services LLC with an aggregate market value of $21,767,964.99 as stated in the filing.
The securities were recently acquired through restricted stock vesting and stock option exercises between 02/13/2026 and 02/17/2026, with consideration described as compensation or cash. Shares outstanding were 2,409,898,936 as of the data provided, which serves as a baseline figure.
A holder of Johnson & Johnson common stock filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 53,931 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 13105233.00, around 02/17/2026.
The securities to be sold were recently acquired from the issuer via restricted stock vesting of 2,283 shares on 02/15/2026 and option exercises totaling 51,648 shares on 02/17/2026. Johnson & Johnson had 2,409,898,936 common shares outstanding at the time referenced.
Johnson & Johnson filed a Form 13F holdings report disclosing its reported institutional holdings. The report lists 17 information-table entries with a total value of $554,625,589. The filing names Johnson & Johnson Innovation - JJDC, Inc. as an included manager and was signed by Marc Larkins on 02-13-2026.
A holder of common stock has filed a notice under Rule 144 to sell 41,559 shares through Fidelity Brokerage Services LLC on or about 02/13/2026 on the NYSE. The filing lists an aggregate market value of 10129245.92 for this planned sale.
The shares relate to option grants from 02/14/2022 and 02/13/2023, with 19,368 and 22,191 shares respectively acquired for cash on 02/13/2026. Common shares outstanding were 2409898936 as of the information provided.
Johnson & Johnson executive Joseph J. Wolk, Exec VP and CFO, was granted 37,463 Performance Share Units on February 9, 2026. These PSUs were awarded under the company’s Long-Term Incentive Plan tied to a grant originally made on February 13, 2023.
The PSUs convert into shares of common stock upon vesting. The 37,463 units reflect the target award adjusted based on achievement of performance conditions in the award agreement, which were certified on February 9, 2026. Following this transaction, Wolk directly holds 37,463 derivative securities.